ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA ® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013.
ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA ® outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA ® . ThromboGenics and Alcon intend to share the costs equally of developing JETREA ® for a number of new vitreoretinal indications.
In Europe, JETREA ® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Alcon has launched JETREA ® in the UK, Germany, Denmark, Norway, Finland and Sweden.ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at http://www.thrombogenics.com. About German Federal Joint Committee (Gemeinsamer Bundesausschuss , G-BA) The Federal Joint Committee (G-BA) is the supreme decision-making body of the so-called self-governing system in Germany. Physicians, dentists, hospitals, sickness funds and patients are represented in the G-BA. The G-BA issues directives and thus determines the benefit package of the statutory health insurance (GKV) covering about 70 million people. Finally, the G-BA is responsible for reimbursement decisions in the GKV. The directives issued by the G-BA are legally binding for insured people as well as for the providers and payers of health care: physicians, hospitals and sickness funds. They are valid for ambulatory treatment, dentistry, hospital care and psychotherapy. Furthermore, the directives define the provision and reimbursement of pharmaceuticals, diagnostic and therapeutic procedures, medical devices and non-medical treatment. In addition, the G-BA has responsibilities regarding quality assurance measures for in- and out-patient care. About Alcon
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV